Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Syneos Health Plummeted Today

By Brian Orelli, PhD – Updated Apr 19, 2019 at 11:32AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biopharmaceutical solutions company is under investigation by the SEC.

What happened

Shares of Syneos Health (SYNH -0.04%) are down 19.7% at 1:40 p.m. EST because the U.S.Securities and Exchange Commission (SEC) is investigating the company's "revenue accounting policies, internal controls, and related matters." The agency wants documents that date back to the beginning of 2017.

So what

Syneos Health helps drug companies develop and sell their drugs; the projects often take multiple quarters to complete. One possibility is that Syneos and the SEC disagree on how much revenue from the contracts should be accounted for in each quarter, so Syneos might have to restate its earnings from previous quarters, but the revenue would eventually be booked in future quarters.

Or it could be something else. Without further information, it's hard to know how serious the investigation will end up being.

SEC logo with stock prices in the background

Image source: Getty Images.

Syneos also said that it needs additional time to complete its 2018 10-K, the end-of-the-year filing with the SEC. The company says management needs additional time to "conduct a review of the company's internal control over financial reporting."

Delaying the filing seems prudent. Worst-case scenario, the SEC determines that Syneos Health has been calculating its finances wrong, and delaying filing for 2018 will allow time to fix it. Best-case scenario, it gives the company time to confirm it's doing everything right. The audit committee for the company's board of directors has also hired outside counsel and accounting advisors to review the company's policies.

Check out the latest Syneos earnings call transcript.

Now what

With the added risk, Syneos deserves a lower valuation until additional information emerges. If the investigation is relatively minor, today could be a great buying opportunity, but without knowing all the details, buying shares now is more akin to gambling than investing.

Brian Orelli and The Motley Fool have no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Syneos Health, Inc. Stock Quote
Syneos Health, Inc.
$48.00 (-0.04%) $0.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.